Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization ScheduleBlackstone to also Purchase $30M of Amicus Common Stock PRINCETON, NJ, – Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a […]